{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:37:16Z","timestamp":1792395436742,"version":"4.4.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,11]]},"DOI":"10.7759\/cureus.82090","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T14:38:21Z","timestamp":1744382301000},"source":"Crossref","is-referenced-by-count":14,"title":["Tumor Microenvironment: A Complex Landscape of Cancer Development and Drug Resistance"],"prefix":"10.7759","author":[{"given":"Sohaila","family":"Fatima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040806","article-title":"Tumor heterogeneity: a great barrier in the age of cancer immunotherapy","volume":"13","author":"El-Sayes N","year":"2021","unstructured":"El-Sayes N, Vito A, Mossman K. Tumor heterogeneity: a great barrier in the age of cancer immunotherapy. Cancers (Basel). 2021, 13:10.3390\/cancers13040806","journal-title":"Cancers (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser KE","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023, 41:374-403. 10.1016\/j.ccell.2023.02.016","journal-title":"Cancer Cell"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06110-6","article-title":"Stromal cells in the tumor microenvironment: accomplices of tumor progression?","volume":"14","author":"Zhao Y","year":"2023","unstructured":"Zhao Y, Shen M, Wu L, et al.. Stromal cells in the tumor microenvironment: accomplices of tumor progression?. Cell Death Dis. 2023, 14:587. 10.1038\/s41419-023-06110-6","journal-title":"Cell Death Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail DF","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013, 19:1423-37. 10.1038\/nm.3394","journal-title":"Nat Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5698","article-title":"Role of tumor microenvironment in cancer progression and therapeutic strategy","volume":"12","author":"Wang Q","year":"2023","unstructured":"Wang Q, Shao X, Zhang Y, et al.. Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med. 2023, 12:11149-65. 10.1002\/cam4.5698","journal-title":"Cancer Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4110\/in.2021.21.e21","article-title":"Mechanisms underlying the role of myeloid-derived suppressor cells in clinical diseases: good or bad","volume":"21","author":"Ge Y","year":"2021","unstructured":"Ge Y, Cheng D, Jia Q, Xiong H, Zhang J. Mechanisms underlying the role of myeloid-derived suppressor cells in clinical diseases: good or bad. Immune Netw. 2021, 21:e21. 10.4110\/in.2021.21.e21","journal-title":"Immune Netw"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.656364","article-title":"Aspects of the tumor microenvironment involved in immune resistance and drug resistance","volume":"12","author":"Khalaf K","year":"2021","unstructured":"Khalaf K, Hana D, Chou JT, Singh C, Mackiewicz A, Kaczmarek M. Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Front Immunol. 2021, 12:656364. 10.3389\/fimmu.2021.656364","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2016.12.010","article-title":"Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters","volume":"17","author":"Dauer P","year":"2017","unstructured":"Dauer P, Nomura A, Saluja A, Banerjee S. Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters. Pancreatology. 2017, 17:7-12. 10.1016\/j.pan.2016.12.010","journal-title":"Pancreatology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.961637","article-title":"Role of hypoxia in the tumor microenvironment and targeted therapy","volume":"12","author":"Chen G","year":"2022","unstructured":"Chen G, Wu K, Li H, Xia D, He T. Role of hypoxia in the tumor microenvironment and targeted therapy. Front Oncol. 2022, 12:961637. 10.3389\/fonc.2022.961637","journal-title":"Front Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.641469","article-title":"Adaptive mechanisms of tumor therapy resistance driven by tumor microenvironment","volume":"9","author":"Wu P","year":"2021","unstructured":"Wu P, Gao W, Su M, Nice EC, Zhang W, Lin J, Xie N. Adaptive mechanisms of tumor therapy resistance driven by tumor microenvironment. Front Cell Dev Biol. 2021, 9:641469. 10.3389\/fcell.2021.641469","journal-title":"Front Cell Dev Biol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-024-01499-w","article-title":"Advancements in single-cell RNA sequencing and spatial transcriptomics for central nervous system disease","volume":"44","author":"Zhang Y","year":"2024","unstructured":"Zhang Y, Li T, Wang G, Ma Y. Advancements in single-cell RNA sequencing and spatial transcriptomics for central nervous system disease. Cell Mol Neurobiol. 2024, 44:65. 10.1007\/s10571-024-01499-w","journal-title":"Cell Mol Neurobiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/abp.2025.13922","article-title":"Advancements in single-cell RNA sequencing and spatial transcriptomics: transforming biomedical research","volume":"72","author":"Molla Desta G","year":"2025","unstructured":"Molla Desta G, Birhanu AG. Advancements in single-cell RNA sequencing and spatial transcriptomics: transforming biomedical research. Acta Biochim Pol. 2025, 72:13922. 10.3389\/abp.2025.13922","journal-title":"Acta Biochim Pol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01744-8","article-title":"Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments","volume":"22","author":"Yuan Z","year":"2023","unstructured":"Yuan Z, Li Y, Zhang S, et al.. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. 2023, 22:48. 10.1186\/s12943-023-01744-8","journal-title":"Mol Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-024-03228-5","article-title":"The influence of endothelial metabolic reprogramming on the tumor microenvironment","volume":"44","author":"Kane K","year":"2025","unstructured":"Kane K, Edwards D, Chen J. The influence of endothelial metabolic reprogramming on the tumor microenvironment. Oncogene. 2025, 44:51-63. 10.1038\/s41388-024-03228-5","journal-title":"Oncogene"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01848-7","article-title":"Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets","volume":"9","author":"Zhang S","year":"2024","unstructured":"Zhang S, Xiao X, Yi Y, et al.. Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. Signal Transduct Target Ther. 2024, 9:149. 10.1038\/s41392-024-01848-7","journal-title":"Signal Transduct Target Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.582","article-title":"Oncogenes and tumor suppressor genes: functions and roles in cancers","volume":"5","author":"Dakal TC","year":"2024","unstructured":"Dakal TC, Dhabhai B, Pant A, et al.. Oncogenes and tumor suppressor genes: functions and roles in cancers. MedComm (2020). 2024, 5:e582. 10.1002\/mco2.582","journal-title":"MedComm (2020)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano R","year":"2020","unstructured":"Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020, 77:1745-70. 10.1007\/s00018-019-03351-7","journal-title":"Cell Mol Life Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9620870","article-title":"Genetic mutations and epigenetic modifications: driving cancer and informing precision medicine","volume":"2017","author":"Coyle KM","year":"2017","unstructured":"Coyle KM, Boudreau JE, Marcato P. Genetic mutations and epigenetic modifications: driving cancer and informing precision medicine. Biomed Res Int. 2017, 2017:9620870. 10.1155\/2017\/9620870","journal-title":"Biomed Res Int"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512222","article-title":"Dysregulated signalling pathways driving anticancer drug resistance","volume":"24","author":"Bou Antoun N","year":"2023","unstructured":"Bou Antoun N, Chioni AM. Dysregulated signalling pathways driving anticancer drug resistance. Int J Mol Sci. 2023, 24:10.3390\/ijms241512222","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2011.01809.x","article-title":"Epigenetic modifications in cancer","volume":"81","author":"Kanwal R","year":"2012","unstructured":"Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin Genet. 2012, 81:303-11. 10.1111\/j.1399-0004.2011.01809.x","journal-title":"Clin Genet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2016.04.001","article-title":"Epigenetic silencing of tumor suppressor genes: paradigms, puzzles, and potential","volume":"1865","author":"Kazanets A","year":"2016","unstructured":"Kazanets A, Shorstova T, Hilmi K, Marques M, Witcher M. Epigenetic silencing of tumor suppressor genes: paradigms, puzzles, and potential. Biochim Biophys Acta. 2016, 1865:275-88. 10.1016\/j.bbcan.2016.04.001","journal-title":"Biochim Biophys Acta"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2009.11.002","article-title":"Tumor heterogeneity: causes and consequences","volume":"1805","author":"Marusyk A","year":"2010","unstructured":"Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010, 1805:105-17. 10.1016\/j.bbcan.2009.11.002","journal-title":"Biochim Biophys Acta"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.21037\/atm-21-1948","article-title":"A narrative review of tumor heterogeneity and challenges to tumor drug therapy","volume":"9","author":"Zhu L","year":"2021","unstructured":"Zhu L, Jiang M, Wang H, et al.. A narrative review of tumor heterogeneity and challenges to tumor drug therapy. Ann Transl Med. 2021, 9:1351. 10.21037\/atm-21-1948","journal-title":"Ann Transl Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.72534","article-title":"Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance","volume":"18","author":"Zhang A","year":"2022","unstructured":"Zhang A, Miao K, Sun H, Deng CX. Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. Int J Biol Sci. 2022, 18:3019-33. 10.7150\/ijbs.72534","journal-title":"Int J Biol Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2022.11.025","article-title":"Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance","volume":"11","author":"Maleki EH","year":"2024","unstructured":"Maleki EH, Bahrami AR, Matin MM. Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance. Genes Dis. 2024, 11:189-204. 10.1016\/j.gendis.2022.11.025","journal-title":"Genes Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01013-0","article-title":"Cancer-associated fibroblasts: from basic science to anticancer therapy","volume":"55","author":"Yang D","year":"2023","unstructured":"Yang D, Liu J, Qian H, Zhuang Q. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp Mol Med. 2023, 55:1322-32. 10.1038\/s12276-023-01013-0","journal-title":"Exp Mol Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.4161\/cam.20875","article-title":"Mesenchymal stem cells in tumor development: emerging roles and concepts","volume":"6","author":"Cuiffo BG","year":"2012","unstructured":"Cuiffo BG, Karnoub AE. Mesenchymal stem cells in tumor development: emerging roles and concepts. Cell Adh Migr. 2012, 6:220-30. 10.4161\/cam.20875","journal-title":"Cell Adh Migr"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1295257","article-title":"Tumor-associated macrophages: an effective player of the tumor microenvironment","volume":"14","author":"Basak U","year":"2023","unstructured":"Basak U, Sarkar T, Mukherjee S, et al.. Tumor-associated macrophages: an effective player of the tumor microenvironment. Front Immunol. 2023, 14:1295257. 10.3389\/fimmu.2023.1295257","journal-title":"Front Immunol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2012.03.004","article-title":"What are regulatory T cells (Treg) regulating in cancer and why?","volume":"22","author":"Whiteside TL","year":"2012","unstructured":"Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why?. Semin Cancer Biol. 2012, 22:327-34. 10.1016\/j.semcancer.2012.03.004","journal-title":"Semin Cancer Biol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1213629","article-title":"Impaired function of dendritic cells within the tumor microenvironment","volume":"14","author":"Xiao Z","year":"2023","unstructured":"Xiao Z, Wang R, Wang X, et al.. Impaired function of dendritic cells within the tumor microenvironment. Front Immunol. 2023, 14:1213629. 10.3389\/fimmu.2023.1213629","journal-title":"Front Immunol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.7150\/jca.2.443","article-title":"Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth, expansion and differentiation of cancer stem cells","volume":"2","author":"Jewett A","year":"2011","unstructured":"Jewett A, Tseng HC. Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth, expansion and differentiation of cancer stem cells. J Cancer. 2011, 2:443-57. 10.7150\/jca.2.443","journal-title":"J Cancer"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954992","article-title":"Managing the TME to improve the efficacy of cancer therapy","volume":"13","author":"Bilotta MT","year":"2022","unstructured":"Bilotta MT, Antignani A, Fitzgerald DJ. Managing the TME to improve the efficacy of cancer therapy. Front Immunol. 2022, 13:954992. 10.3389\/fimmu.2022.954992","journal-title":"Front Immunol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.868695","article-title":"The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment","volume":"13","author":"Kim SK","year":"2022","unstructured":"Kim SK, Cho SW. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. Front Pharmacol. 2022, 13:868695. 10.3389\/fphar.2022.868695","journal-title":"Front Pharmacol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051172","article-title":"Inducing angiogenesis, a key step in cancer vascularization, and treatment approaches","volume":"12","author":"Saman H","year":"2020","unstructured":"Saman H, Raza SS, Uddin S, Rasul K. Inducing angiogenesis, a key step in cancer vascularization, and treatment approaches. Cancers (Basel). 2020, 12:10.3390\/cancers12051172","journal-title":"Cancers (Basel)"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen Z","year":"2023","unstructured":"Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023, 8:70. 10.1038\/s41392-023-01332-8","journal-title":"Signal Transduct Target Ther"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143466","article-title":"Extracellular matrices and cancer-associated fibroblasts: targets for cancer diagnosis and therapy?","volume":"13","author":"Belhabib I","year":"2021","unstructured":"Belhabib I, Zaghdoudi S, Lac C, Bousquet C, Jean C. Extracellular matrices and cancer-associated fibroblasts: targets for cancer diagnosis and therapy?. Cancers (Basel). 2021, 13:10.3390\/cancers13143466","journal-title":"Cancers (Basel)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a005058","article-title":"Extracellular matrix degradation and remodeling in development and disease","volume":"3","author":"Lu P","year":"2011","unstructured":"Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol. 2011, 3:10.1101\/cshperspect.a005058","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0002","article-title":"The interplay between extracellular matrix remodeling and cancer therapeutics","volume":"14","author":"Prakash J","year":"2024","unstructured":"Prakash J, Shaked Y. The interplay between extracellular matrix remodeling and cancer therapeutics. Cancer Discov. 2024, 14:1375-88. 10.1158\/2159-8290.CD-24-0002","journal-title":"Cancer Discov"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102446","article-title":"Role of cytokines and chemokines in angiogenesis in a tumor context","volume":"14","author":"Geindreau M","year":"2022","unstructured":"Geindreau M, Bruchard M, Vegran F. Role of cytokines and chemokines in angiogenesis in a tumor context. Cancers (Basel). 2022, 14:10.3390\/cancers14102446","journal-title":"Cancers (Basel)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He Y","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, Li B. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 2021, 6:425. 10.1038\/s41392-021-00828-5","journal-title":"Signal Transduct Target Ther"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.023820","article-title":"The extracellular matrix at a glance","volume":"123","author":"Frantz C","year":"2010","unstructured":"Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010, 123:4195-200. 10.1242\/jcs.023820","journal-title":"J Cell Sci"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2327","article-title":"Crosstalk between cancer and immune cells: role of tumor-associated macrophages in the tumor microenvironment","volume":"8","author":"Wang J","year":"2019","unstructured":"Wang J, Li D, Cang H, Guo B. Crosstalk between cancer and immune cells: role of tumor-associated macrophages in the tumor microenvironment. Cancer Med. 2019, 8:4709-21. 10.1002\/cam4.2327","journal-title":"Cancer Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18794-x","article-title":"Concepts of extracellular matrix remodelling in tumour progression and metastasis","volume":"11","author":"Winkler J","year":"2020","unstructured":"Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020, 11:5120. 10.1038\/s41467-020-18794-x","journal-title":"Nat Commun"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01252-0","article-title":"Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy","volume":"15","author":"Jiang Y","year":"2022","unstructured":"Jiang Y, Zhang H, Wang J, Liu Y, Luo T, Hua H. Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. J Hematol Oncol. 2022, 15:34. 10.1186\/s13045-022-01252-0","journal-title":"J Hematol Oncol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.01.015","article-title":"Cancer metabolism drives a stromal regenerative response","volume":"29","author":"Schw\u00f6rer S","year":"2019","unstructured":"Schw\u00f6rer S, Vardhana SA, Thompson CB. Cancer metabolism drives a stromal regenerative response. Cell Metab. 2019, 29:576-91. 10.1016\/j.cmet.2019.01.015","journal-title":"Cell Metab"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12036","article-title":"The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells","volume":"138","author":"Lindau D","year":"2013","unstructured":"Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013, 138:105-15. 10.1111\/imm.12036","journal-title":"Immunology"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines4030028","article-title":"Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting","volume":"4","author":"Chaudhary B","year":"2016","unstructured":"Chaudhary B, Elkord E. Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines (Basel). 2016, 4:10.3390\/vaccines4030028","journal-title":"Vaccines (Basel)"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1593\/neo.91302","article-title":"Stromal cells and integrins: conforming to the needs of the tumor microenvironment","volume":"11","author":"Alphonso A","year":"2009","unstructured":"Alphonso A, Alahari SK. Stromal cells and integrins: conforming to the needs of the tumor microenvironment. Neoplasia. 2009, 11:1264-71. 10.1593\/neo.91302","journal-title":"Neoplasia"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100773","article-title":"Epithelial-mesenchymal transition in cancer: a historical overview","volume":"13","author":"Ribatti D","year":"2020","unstructured":"Ribatti D, Tamma R, Annese T. Epithelial-mesenchymal transition in cancer: a historical overview. Transl Oncol. 2020, 13:100773. 10.1016\/j.tranon.2020.100773","journal-title":"Transl Oncol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00238.2015","article-title":"Tumor cell intravasation","volume":"311","author":"Chiang SP","year":"2016","unstructured":"Chiang SP, Cabrera RM, Segall JE. Tumor cell intravasation. Am J Physiol Cell Physiol. 2016, 311:C1-C14. 10.1152\/ajpcell.00238.2015","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1038\/bonekey.2012.80","article-title":"The pre-metastatic niche: is metastasis random?","volume":"1","author":"Cox TR","year":"2012","unstructured":"Cox TR, Gartland A, Erler JT. The pre-metastatic niche: is metastasis random?. Bonekey Rep. 2012, 1:80. 10.1038\/bonekey.2012.80","journal-title":"Bonekey Rep"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00584","article-title":"Resistance to anti-angiogenic therapies: a mechanism depending on the time of exposure to the drugs","volume":"8","author":"Montemagno C","year":"2020","unstructured":"Montemagno C, Pag\u00e8s G. Resistance to anti-angiogenic therapies: a mechanism depending on the time of exposure to the drugs. Front Cell Dev Biol. 2020, 8:584. 10.3389\/fcell.2020.00584","journal-title":"Front Cell Dev Biol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand Y","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SM, et al.. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022, 29:3044-60. 10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4508794","article-title":"Current challenges in cancer immunotherapy: multimodal approaches to improve efficacy and patient response rates","volume":"2019","author":"Sambi M","year":"2019","unstructured":"Sambi M, Bagheri L, Szewczuk MR. Current challenges in cancer immunotherapy: multimodal approaches to improve efficacy and patient response rates. J Oncol. 2019, 2019:4508794. 10.1155\/2019\/4508794","journal-title":"J Oncol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103226","article-title":"Targeting tumor-associated macrophages in anti-cancer therapies: convincing the traitors to do the right thing","volume":"9","author":"Belgiovine C","year":"2020","unstructured":"Belgiovine C, Digifico E, Anfray C, Ummarino A, Torres And\u00f3n F. Targeting tumor-associated macrophages in anti-cancer therapies: convincing the traitors to do the right thing. J Clin Med. 2020, 9:10.3390\/jcm9103226","journal-title":"J Clin Med"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1080\/09553002.2019.1589653","article-title":"The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression","volume":"95","author":"Vaupel P","year":"2019","unstructured":"Vaupel P, Schmidberger H, Mayer A. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression. Int J Radiat Biol. 2019, 95:912-9. 10.1080\/09553002.2019.1589653","journal-title":"Int J Radiat Biol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-65768-0_15","article-title":"Targeting metabolic cross talk between cancer cells and cancer-associated fibroblasts","volume":"1311","author":"Jung JG","year":"2021","unstructured":"Jung JG, Le A. Targeting metabolic cross talk between cancer cells and cancer-associated fibroblasts. Adv Exp Med Biol. 2021, 1311:205-14. 10.1007\/978-3-030-65768-0_15","journal-title":"Adv Exp Med Biol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.3390\/ph17020195","article-title":"Targeting hypoxia-inducible factor-1 (HIF-1) in cancer: emerging therapeutic strategies and pathway regulation","volume":"17","author":"Qannita RA","year":"2024","unstructured":"Qannita RA, Alalami AI, Harb AA, et al.. Targeting hypoxia-inducible factor-1 (HIF-1) in cancer: emerging therapeutic strategies and pathway regulation. Pharmaceuticals (Basel). 2024, 17:10.3390\/ph17020195","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.809304","article-title":"Effective combinations of immunotherapy and radiotherapy for cancer treatment","volume":"12","author":"Yu S","year":"2022","unstructured":"Yu S, Wang Y, He P, et al.. Effective combinations of immunotherapy and radiotherapy for cancer treatment. Front Oncol. 2022, 12:809304. 10.3389\/fonc.2022.809304","journal-title":"Front Oncol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.705280","article-title":"Potential strategies to improve the effectiveness of drug therapy by changing factors related to tumor microenvironment","volume":"9","author":"Cao D","year":"2021","unstructured":"Cao D, Naiyila X, Li J, et al.. Potential strategies to improve the effectiveness of drug therapy by changing factors related to tumor microenvironment. Front Cell Dev Biol. 2021, 9:705280. 10.3389\/fcell.2021.705280","journal-title":"Front Cell Dev Biol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.2306\/scienceasia1513-1874.2020.092","article-title":"Cancer chemoresistance and therapeutic strategies targeting tumor microenvironment","volume":"46","author":"Palliyage GH","year":"2020","unstructured":"Palliyage GH, Ghosh R, Rojanasakul Y. Cancer chemoresistance and therapeutic strategies targeting tumor microenvironment. 2020, 46:639-49. 10.2306\/scienceasia1513-1874.2020.092"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713618","article-title":"Targeted therapy for cancers: from ongoing clinical trials to FDA-approved drugs","volume":"24","author":"Choi HY","year":"2023","unstructured":"Choi HY, Chang JE. Targeted therapy for cancers: from ongoing clinical trials to FDA-approved drugs. Int J Mol Sci. 2023, 24:10.3390\/ijms241713618","journal-title":"Int J Mol Sci"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.32604\/or.2024.055161","article-title":"Redefining the tumor microenvironment with emerging therapeutic strategies","volume":"32","author":"Xu S","year":"2024","unstructured":"Xu S, Li X, Ma W. Redefining the tumor microenvironment with emerging therapeutic strategies. Oncol Res. 2024, 32:1701-8. 10.32604\/or.2024.055161","journal-title":"Oncol Res"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.2007.3.2.341","article-title":"Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)","volume":"3","author":"Le Tourneau C","year":"2007","unstructured":"Le Tourneau C, Raymond E, Faivre S. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Ther Clin Risk Manag. 2007, 3:341-8. 10.2147\/tcrm.2007.3.2.341","journal-title":"Ther Clin Risk Manag"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.4103\/1319-3767.37808","article-title":"Sorafenib in the treatment of advanced hepatocellular carcinoma","volume":"14","author":"Ben Mousa A","year":"2008","unstructured":"Ben Mousa A. Sorafenib in the treatment of advanced hepatocellular carcinoma. Saudi J Gastroenterol. 2008, 14:40-2. 10.4103\/1319-3767.37808","journal-title":"Saudi J Gastroenterol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts PJ","year":"2007","unstructured":"Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007, 26:3291-310. 10.1038\/sj.onc.1210422","journal-title":"Oncogene"},{"key":"ref68","unstructured":"https.\/\/www.cancer.org\/content\/dam\/CRC\/PDF\/Public\/6678.00.pdf. (2024). Accessed: March 20, 2025: https:\/\/www.cancer.org\/cancer\/managing-cancer\/treatment-types\/immunotherapy\/immune-checkpoint-inhibitors.html."},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0040","article-title":"In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates","volume":"2","author":"Wang C","year":"2014","unstructured":"Wang C, Thudium KB, Han M, et al.. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014, 2:846-56. 10.1158\/2326-6066.CIR-14-0040","journal-title":"Cancer Immunol Res"},{"key":"ref70","article-title":"Nivolumab","author":"Rendon A","year":"2025","unstructured":"Rendon A, Rayi A. Nivolumab. StatPearls. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu ZL","year":"2023","unstructured":"Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023, 8:198. 10.1038\/s41392-023-01460-1","journal-title":"Signal Transduct Target Ther"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115688","article-title":"CAR-T cell therapy: from the shop to cancer therapy","volume":"24","author":"Uscanga-Palomeque AC","year":"2023","unstructured":"Uscanga-Palomeque AC, Ch\u00e1vez-Escamilla AK, Alvizo-B\u00e1ez CA, et al.. CAR-T cell therapy: from the shop to cancer therapy. Int J Mol Sci. 2023, 24:10.3390\/ijms242115688","journal-title":"Int J Mol Sci"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz MZ","year":"2021","unstructured":"Wojtukiewicz MZ, Rek MM, Karpowicz K, et al.. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev. 2021, 40:949-82. 10.1007\/s10555-021-09976-0","journal-title":"Cancer Metastasis Rev"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews LP","year":"2017","unstructured":"Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017, 276:80-96. 10.1111\/imr.12519","journal-title":"Immunol Rev"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1177\/15330338211036304","article-title":"Hypoxia and the tumor microenvironment","volume":"20","author":"Li Y","year":"2021","unstructured":"Li Y, Zhao L, Li XF. Hypoxia and the tumor microenvironment. Technol Cancer Res Treat. 2021, 20:15330338211036304. 10.1177\/15330338211036304","journal-title":"Technol Cancer Res Treat"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers","volume":"31","author":"Jain RK","year":"2013","unstructured":"Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013, 31:2205-18. 10.1200\/JCO.2012.46.3653","journal-title":"J Clin Oncol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.6497","article-title":"Cancer associated fibroblasts: an essential role in the tumor microenvironment","volume":"14","author":"Tao L","year":"2017","unstructured":"Tao L, Huang G, Song H, Chen Y, Chen L. Cancer associated fibroblasts: an essential role in the tumor microenvironment. Oncol Lett. 2017, 14:2611-20. 10.3892\/ol.2017.6497","journal-title":"Oncol Lett"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1063\/5.0030693","article-title":"Modeling the tumor immune microenvironment for drug discovery using 3D culture","volume":"5","author":"Lee JY","year":"2021","unstructured":"Lee JY, Chaudhuri O. Modeling the tumor immune microenvironment for drug discovery using 3D culture. APL Bioeng. 2021, 5:010903. 10.1063\/5.0030693","journal-title":"APL Bioeng"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00992","article-title":"Emerging challenges of preclinical models of anti-tumor immunotherapeutic strategies utilizing V\u03b39V\u03b42 T cells","volume":"11","author":"Joalland N","year":"2020","unstructured":"Joalland N, Scotet E. Emerging challenges of preclinical models of anti-tumor immunotherapeutic strategies utilizing V\u03b39V\u03b42 T cells. Front Immunol. 2020, 11:992. 10.3389\/fimmu.2020.00992","journal-title":"Front Immunol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026781","article-title":"Tumor microenvironment and differential responses to therapy","volume":"7","author":"Hirata E","year":"2017","unstructured":"Hirata E, Sahai E. Tumor microenvironment and differential responses to therapy. Cold Spring Harb Perspect Med. 2017, 7:10.1101\/cshperspect.a026781","journal-title":"Cold Spring Harb Perspect Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/357991-tumor-microenvironment-a-complex-landscape-of-cancer-development-and-drug-resistance","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T14:38:23Z","timestamp":1744382303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/357991-tumor-microenvironment-a-complex-landscape-of-cancer-development-and-drug-resistance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":80,"URL":"https:\/\/doi.org\/10.7759\/cureus.82090","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,11]]}}}